Amino Acids and Sorbitol in Liver Cirrhosis

BCAA Supplementation: Evidence-Based Recommendations

The European Association for the Study of the Liver (EASL) guidelines recommend that protein intake should be sufficiently rich in branched-chain amino acids to prevent or reverse muscle loss in decompensated cirrhotic patients 1, 2
BCAAs are specifically indicated for decompensated cirrhotic patients who cannot achieve adequate protein intake (1.2-1.5 g/kg/day) through diet alone, with the goal of preventing or reversing muscle loss 1, 2
Sarcopenia affects 50-60% of cirrhotic patients and is associated with higher rates of complications, morbidity, and mortality, making BCAA supplementation a critical component of their care 1, 2
BCAA supplementation should be used in decompensated cirrhotic patients to achieve adequate nitrogen intake when dietary protein goals cannot be met, at a recommended dose of 0.25 g/kg/day for patients with hepatic encephalopathy is not applicable due to ignore ref, however 3
Late evening oral nutritional supplementation should be included in the dietary regime of malnourished decompensated cirrhotic patients 3

When oral or enteral nutrition is ineffective or not feasible, parenteral nutrition should be used, with BCAA-enriched solutions containing 35-45% BCAAs recommended for patients with overt hepatic encephalopathy requiring parenteral nutrition 4
Meta-analyses show improvement in mental state with BCAA-enriched solutions, but no definitive survival benefit 4

There is no evidence supporting the use of sorbitol in liver cirrhosis, and it should be avoided due to its potential to cause osmotic diarrhea, dehydration, and electrolyte abnormalities 1, 2, 4, 5, 6, 3
Osmotic diarrhea from sorbitol could worsen dehydration and electrolyte abnormalities in patients with advanced liver disease 1

Nutritional intervention improves nutritional status, hepatic encephalopathy, survival, and quality of life in people with cirrhosis, with a 6-month dietitian-supported home-based intensive high-calorie, protein-rich nutrition therapy associated with improvement in frailty, sarcopenia, and liver disease scores and survival 1, 2
Do not delay nutritional intervention—cirrhotic patients exhibit hepatic glycogen depletion and resort to protein catabolism as early as after an overnight fast, highlighting the importance of prompt nutritional support 4

The recommended dose of oral BCAAs for patients with liver cirrhosis and hepatic encephalopathy is 0.25 g/kg/day, or approximately 30-34 g/day for most adults, according to the Clinical and Molecular Hepatology guidelines 7, 8
Standard therapeutic dose for management of overt hepatic encephalopathy is 0.25 g/kg/day orally 7
Alternative dosing of 34 g/day has been shown to reduce hospitalizations due to complications including infection, gastrointestinal bleeding, ascites, and hepatic encephalopathy in patients with symptomatic alcoholic cirrhosis 8, 9
BCAA-enriched solutions containing 35-45% BCAAs are recommended for patients with overt hepatic encephalopathy who require parenteral nutrition, as suggested by Clinical Nutrition guidelines 10

Total protein intake should be 1.2-1.5 g/kg/day from diverse sources, with BCAAs naturally present in protein-containing foods, as recommended by the American Association for the Study of Liver Diseases 11
The American Association for the Study of Liver Diseases does not recommend long-term BCAA supplementation beyond achieving recommended protein intake targets from diverse protein sources 11

Long-term supplementation (12-24 months) has demonstrated benefits in preventing progressive hepatic failure and improving quality of life in cirrhotic patients, with doses of 0.20-0.25 g/kg/day or 30 g/day 12
The evidence for mortality benefit remains equivocal, with meta-analyses showing improvement in mental state but no definitive survival advantage 10, 11
Cost and palatability may significantly affect patient compliance with oral BCAA supplements, as they are not reimbursed in most countries 12

In well-nourished cirrhotic patients who can achieve adequate protein intake (1.2-1.5 g/kg/day) through diverse dietary sources, supplemental BCAAs beyond this target are not recommended, as stated by the American Association for the Study of Liver Diseases 11